

In addition to the arguments raised in the February 27, 2002 response, Applicants respectfully note that claims 7 and 8 are both dependent from claim 1. As is clear from Applicants' specification and claims, the claimed invention is based on the discovery that the stress proteins hsp110 and grp170, when complexed with tumor antigens, are remarkably effective as tumor vaccines (see page 15, lines 15-16). Claims 7 and 8 both relate to combination of this inventive subject matter (as recited in independent claim 1) with a member of a group of known stress proteins. Applicants maintain that no significant additional burden is placed on the Examiner to provide a complete examination of the subject matter of claims 7 and 8.


Consequently, Applicants respectfully request that the Examiner reconsider and withdraw the election of species requirement, as well as the restriction requirement. It is also submitted that this application is now in good order for allowance and such allowance is respectfully solicited. Should the Examiner believe minor matters remain that can be resolved by telephone, the Examiner is urged to call Applicants' undersigned attorney.

Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive Wcst, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: March 28, 2002

By:   
Name: Karen S. Canady  
Reg. No.: 39,927

KSC/sjm/amb

G&C 126.1-US-U3